Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +172.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Revenue changed +36.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed -67.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating margin changed -5790 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Net income changed -90.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Cash & equivalents changed +66.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Gross profit changed +35.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Gross margin changed -65 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.